228 related articles for article (PubMed ID: 34547384)
1. Dual BET/HDAC inhibition to relieve neuropathic pain: Recent advances, perspectives, and future opportunities.
Romanelli MN; Borgonetti V; Galeotti N
Pharmacol Res; 2021 Nov; 173():105901. PubMed ID: 34547384
[TBL] [Abstract][Full Text] [Related]
2. Dual HDAC/BRD4 Inhibitors Relieves Neuropathic Pain by Attenuating Inflammatory Response in Microglia After Spared Nerve Injury.
Borgonetti V; Meacci E; Pierucci F; Romanelli MN; Galeotti N
Neurotherapeutics; 2022 Sep; 19(5):1634-1648. PubMed ID: 35501470
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of histone deacetylases and BET family proteins as epigenetic therapy for nerve injury-induced neuropathic pain.
Borgonetti V; Galeotti N
Pharmacol Res; 2021 Mar; 165():105431. PubMed ID: 33529752
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase as emerging pharmacological therapeutic target for neuropathic pain: From epigenetic to selective drugs.
Zhang W; Jiao B; Yu S; Zhang C; Zhang K; Liu B; Zhang X
CNS Neurosci Ther; 2024 May; 30(5):e14745. PubMed ID: 38715326
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor-induced emergence of synaptic δ-opioid receptors and behavioral antinociception in persistent neuropathic pain.
Tao W; Zhou W; Wang Y; Sun T; Wang H; Zhang Z; Jin Y
Neuroscience; 2016 Dec; 339():54-63. PubMed ID: 27646288
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors relieve morphine resistance in neuropathic pain after peripheral nerve injury.
Uchida H; Matsushita Y; Araki K; Mukae T; Ueda H
J Pharmacol Sci; 2015 Aug; 128(4):208-11. PubMed ID: 26318673
[TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylase Inhibitors and Diabetic Kidney Disease.
Hadden MJ; Advani A
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30189630
[TBL] [Abstract][Full Text] [Related]
8. BET inhibitors: a novel epigenetic approach.
Doroshow DB; Eder JP; LoRusso PM
Ann Oncol; 2017 Aug; 28(8):1776-1787. PubMed ID: 28838216
[TBL] [Abstract][Full Text] [Related]
9. HDAC-targeting epigenetic modulators for cancer immunotherapy.
Cheng B; Pan W; Xiao Y; Ding Z; Zhou Y; Fei X; Liu J; Su Z; Peng X; Chen J
Eur J Med Chem; 2024 Feb; 265():116129. PubMed ID: 38211468
[TBL] [Abstract][Full Text] [Related]
10. Targeting epigenetic DNA and histone modifications to treat kidney disease.
Fontecha-Barriuso M; Martin-Sanchez D; Ruiz-Andres O; Poveda J; Sanchez-Niño MD; Valiño-Rivas L; Ruiz-Ortega M; Ortiz A; Sanz AB
Nephrol Dial Transplant; 2018 Nov; 33(11):1875-1886. PubMed ID: 29534238
[TBL] [Abstract][Full Text] [Related]
11. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics.
Hadnagy A; Beaulieu R; Balicki D
Mol Cancer Ther; 2008 Apr; 7(4):740-8. PubMed ID: 18413789
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibition inhibits brachial plexus avulsion-induced neuropathic pain.
Zhao Y; Wu T
Muscle Nerve; 2018 Sep; 58(3):434-440. PubMed ID: 29742796
[TBL] [Abstract][Full Text] [Related]
13. Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer.
He S; Dong G; Li Y; Wu S; Wang W; Sheng C
Angew Chem Int Ed Engl; 2020 Feb; 59(8):3028-3032. PubMed ID: 31943585
[TBL] [Abstract][Full Text] [Related]
14. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic Priming and Development of New Combination Therapy Approaches.
Meneceur S; Grunewald CM; Niegisch G; Hoffmann MJ
Methods Mol Biol; 2023; 2684():259-281. PubMed ID: 37410240
[TBL] [Abstract][Full Text] [Related]
16. Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells.
Enßle JC; Boedicker C; Wanior M; Vogler M; Knapp S; Fulda S
Cancer Lett; 2018 Aug; 428():160-172. PubMed ID: 29709701
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Santini V; Gozzini A; Ferrari G
Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present).
Zhao C; Dong H; Xu Q; Zhang Y
Expert Opin Ther Pat; 2020 Apr; 30(4):263-274. PubMed ID: 32008402
[No Abstract] [Full Text] [Related]
19. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
20. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
